Mechanism of Action of Amantadine in Parkinson's Disease
Amantadine functions primarily as a weak, non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist, combined with both direct and indirect dopaminergic effects, which together account for its antiparkinsonian activity. 1
Primary Mechanisms
NMDA Receptor Antagonism
The most well-established mechanism is non-competitive antagonism of NMDA receptors (Ki = 10µM), which modulates glutamatergic excitatory transmission in the basal ganglia 1. This glutamatergic blockade helps restore the balance between dopaminergic and glutamatergic systems that is disrupted in Parkinson's disease 2. The NMDA receptor blockade occurs at therapeutically relevant (low micromolar) concentrations 2.
Dopaminergic Effects
Amantadine exerts both direct and indirect effects on dopamine neurons 1:
- Indirect dopamine release: Promotes release of dopamine from presynaptic terminals
- Direct dopamine receptor stimulation: Acts as a weak dopamine receptor agonist
- Possible dopamine reuptake inhibition: Though this effect is considered too weak to substantially contribute to clinical efficacy 3
The relative importance of these dopaminergic mechanisms appears to favor the indirect dopamine-releasing action over direct receptor stimulation by approximately 4:1 3.
Additional Mechanisms
Anticholinergic Activity
Although amantadine does not possess direct anticholinergic activity in animal studies, it clinically exhibits anticholinergic-like effects including dry mouth, urinary retention, and constipation 1. This contributes to its utility in treating drug-induced extrapyramidal symptoms 4.
Anti-inflammatory Effects
Emerging evidence suggests amantadine may inhibit microglial activation and neuroinflammation, reducing expression of proinflammatory mediators 5. This provides a potential neuroprotective mechanism, though clinical significance requires further validation.
Clinical Implications
The dual glutamatergic and dopaminergic properties explain amantadine's unique therapeutic profile:
- Symptomatic improvement of parkinsonian motor signs (bradykinesia, tremor, rigidity) through dopaminergic enhancement
- Reduction of levodopa-induced dyskinesias through NMDA receptor blockade 6, 7
- Treatment of motor fluctuations by modulating both neurotransmitter systems 8
Important Caveats
The exact quantitative contribution of each mechanism remains incompletely defined. While amantadine is less effective than levodopa for motor symptoms 1, its multi-modal mechanism makes it particularly valuable as adjunctive therapy, especially for managing dyskinesias where it demonstrates clear efficacy 7, 9.
The extended-release formulation achieves higher and more continuous brain delivery, enhancing clinical benefits for both dyskinesia reduction and "OFF" time improvement 10.